RETAROS
– Retatrutide – 15 MG / VIAL – 2 ML VIAL – Pharmacom LABS
- RETAROS 15 MG is a retatrutide-based product designed for advanced weight management and metabolic improvement.
- Retatrutide is a triple incretin receptor agonist (GLP-1, GIP, and Glucagon), providing a comprehensive approach to appetite control, energy expenditure, and glucose regulation.
- The compound reduces appetite, increases satiety, and significantly lowers caloric intake while enhancing fat oxidation and overall metabolic rate.
- Retatrutide improves insulin sensitivity and glycemic control, contributing to better blood glucose regulation.
- Clinical observations show positive effects on lipid profiles, reductions in systolic blood pressure, and a lowered cardiovascular risk associated with excess body weight.
- The majority of weight loss observed during retatrutide administration is primarily due to adipose tissue reduction.
- The long active half-life allows for once-weekly subcutaneous injection.
- RETAROS does not interfere with sex hormone production, making it suitable for use by both men and women, and no post-cycle therapy (PCT) is required after discontinuation.
- RETAROS is supplied as a peptide dry powder and must be reconstituted with water for injection before use.
Retatrutide
| Parameter | Specification |
|---|---|
| Active half-life | ~6 days |
| Classification | GLP-1 / GIP / Glucagon receptor agonist |
| Dosage | 2.5–15 mg/week |
| Acne | No |
| Water Retention | No |
| HBR | No |
| Hepatotoxicity | No |
| Aromatization | No |
| Brands | Pharmacom LABS |